Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
MRSN Stock Price Fell 29.49%: Why It Happened
08:56am, Wednesday, 06'th Jan 2021
The stock price of Mersana Therapeutics Inc (NASDAQ: MRSN) fell 28.49% as it went from a previous close of $26.48 to $18.66 per share on January 5. This is why it happened.
Mersana Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 06'th Jan 2021
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Why Mersana Therapeutics Stock Is Crashing Today
01:08pm, Tuesday, 05'th Jan 2021
The company reported disappointing clinical results.
Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones
10:00am, Tuesday, 05'th Jan 2021
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
5 Biotech Stocks That Have Gained More Than 200% in 2020
10:32am, Tuesday, 29'th Dec 2020
Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.
Mersana Therapeutics to Host Virtual Analyst and Investor Event
08:00am, Thursday, 17'th Dec 2020
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
These Were the 5 Best Cancer Stocks Of 2020
08:29am, Monday, 07'th Dec 2020
Biotech investors had more than just vaccines to think about this year.
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 02'nd Dec 2020
CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics Reports Preclinical Data from Immunosynthen STING-Agonist ADC Platform and Pipeline
09:00am, Wednesday, 11'th Nov 2020
CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q3 2020 Results - Earnings Call Transcript
12:58pm, Monday, 09'th Nov 2020
Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q3 2020 Results - Earnings Call Transcript
Mersana Therapeutics to Host Webinar Highlighting Immunosynthen STING-Agonist ADC Platform and Pipeline
07:30am, Monday, 09'th Nov 2020
- Webcast to be held on Monday, November 16, 2020, at 8:00 a.m. ET - - Webcast to be held on Monday, November 16, 2020, at 8:00 a.m. ET -
Mersana Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
06:00am, Monday, 09'th Nov 2020
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference
08:00am, Wednesday, 04'th Nov 2020
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates
08:00am, Monday, 02'nd Nov 2020
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr
Advanced Dermatology and Cosmetic Surgery Announces the Appointment of Brian T. Griffin as Chief Executive Officer
12:00am, Wednesday, 16'th Sep 2020
Advanced Dermatology and Cosmetic Surgery (ADCS), a national leader in dermatology care, today announced that Brian T. Griffin has been appointed as C
